Latest Breaking News On - Foghorn therapeutic - Page 2 : comparemela.com

HC Wainwright Brokers Reduce Earnings Estimates for Foghorn Therapeutics Inc (NASDAQ:FHTX)

Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) – Analysts at HC Wainwright reduced their Q2 2023 earnings per share (EPS) estimates for Foghorn Therapeutics in a research report issued to clients and investors on Tuesday, May 9th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.78) per share for […]

United statesRaymond james associatesMillennium managementBarclays plcRussell investments group ltdFoghorn therapeutics incMan groupFoghorn therapeuticsGet ratingFoghorn therapeuticInvestments groupTherapeutics incGene traffic controlFoghorn therapeutics dailyNasdaq fhtxEarnings estimates

Wedbush Trims Foghorn Therapeutics (NASDAQ:FHTX) Target Price to $15 00

Foghorn Therapeutics (NASDAQ:FHTX – Get Rating) had its target price reduced by Wedbush from $20.00 to $15.00 in a research note published on Tuesday morning, The Fly reports. Wedbush also issued estimates for Foghorn Therapeutics’ FY2025 earnings at ($1.93) EPS, FY2026 earnings at ($1.94) EPS and FY2027 earnings at $0.84 EPS. FHTX has been the […]

United statesWells fargo companyFoghorn therapeutics incAmerica corpTower research capitalBarclays plcFoghorn therapeuticsGet ratingFoghorn therapeuticModerate buyTherapeutics stock downResearch capitalTherapeutics incGene traffic controlFoghorn therapeutics dailyNasdaq fhtx

FDA Places Full Hold on Foghorn s Phase I Study in Relapsed/Refractory AML/MDS

FDA Places Full Hold on Foghorn s Phase I Study in Relapsed/Refractory AML/MDS
globalgenes.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalgenes.org Daily Mail and Mail on Sunday newspapers.

United statesAdrian gottschalkDrug administrationFoghorn therapeuticGene traffic control

Brokerages Anticipate Foghorn Therapeutics Inc (NASDAQ:FHTX) Will Post Quarterly Sales of $14 38 Million

Brokerages expect that Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) will report $14.38 million in sales for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Foghorn Therapeutics’ earnings, with the highest sales estimate coming in at $18.75 million and the lowest estimate coming in at $10.00 million. Foghorn Therapeutics posted […]

United statesMorgan stanleyLife insurance coZacks investment researchFoghorn therapeutics incAmerica corpGoldman sachs groupCitigroup incRoyal bankFoghorn therapeuticsGet ratingFoghorn therapeuticInvestment researchTherapeutics incGene traffic controlNasdaq fhtx

$14 40 Million in Sales Expected for Foghorn Therapeutics Inc (NASDAQ:FHTX) This Quarter

Wall Street analysts expect Foghorn Therapeutics Inc. (NASDAQ:FHTX – Get Rating) to announce $14.40 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Foghorn Therapeutics’ earnings, with estimates ranging from $10.00 million to $18.80 million. Foghorn Therapeutics reported sales of $280,000.00 during the same quarter last […]

Zacks investment researchFoghorn therapeutics incNewsquare capitalBlackrock incJpmorgan chase coWells fargo companyRaymond james associatesFoghorn therapeutics company profile get ratingWall streetFoghorn therapeuticsGet ratingZacks investmentFoghorn therapeuticInvestment researchSquare capitalWells fargo